High-Risk Clinical Trials

80 recruitingLast updated: June 18, 2026

There are 80 actively recruiting high-risk clinical trials across 25 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1. Top locations include Guangzhou, Guangdong, China, Shanghai, Shanghai Municipality, China, Boston, Massachusetts, United States. Updated daily from ClinicalTrials.gov.


High-Risk Trials at a Glance

80 actively recruiting trials for high-risk are listed on ClinicalTrialsFinder across 6 cities in 25 countries. The largest study group is Phase 2 with 28 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Boston. Lead sponsors running high-risk studies include Fudan University, Massachusetts General Hospital, and Shanghai Hengrui Pharmaceutical Co., Ltd..

Browse high-risk trials by phase

Treatments under study

About High-Risk Clinical Trials

Looking for clinical trials for High-Risk? There are currently 6 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new High-Risk trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about High-Risk clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 80 trials

Recruiting
Phase 2

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

Prostate CancerHigh-risk Prostate Cancer
Icahn School of Medicine at Mount Sinai40 enrolled1 locationNCT07027124
Recruiting
Phase 2

Immunoprevention for High-risk Lung Lesions

High-risk Lung Nodules
Robert Samstein59 enrolled1 locationNCT07284485
Recruiting
Not Applicable

ANCHOR Validation Trial in High-Risk Multidisciplinary Care

TelemedicineClinical Decision SupportHigh-Risk Multidisciplinary Care+1 more
Waymark240 enrolled1 locationNCT07597499
Recruiting
Phase 2

Androgen-responsive POSLUMA-guided Intra-prostatic Boost

Prostate CancerHigh-risk Prostate CancerIntermediate Risk Prostate Cancer
Martin T. King, MD, PhD23 enrolled4 locationsNCT07393867
Recruiting
Phase 1Phase 2

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

High-Risk Localized Soft Tissue Sarcoma
Fudan University52 enrolled1 locationNCT05774275
Recruiting
Not Applicable

The Metabolic Effects of Intermittent Fasting

Normal and Overweight Individuals at High-risk of Diabetes
University of Pittsburgh90 enrolled1 locationNCT05722873
Recruiting
Phase 3

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal CarcinomaHigh-Risk CancerMaintenance Therapy
Jiangxi Provincial Cancer Hospital264 enrolled3 locationsNCT06277050
Recruiting
Phase 2

Phase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities

HPV InfectionASC-USUterine Cervical Dysplasia+3 more
Amplexd Therapeutics, Inc.45 enrolled1 locationNCT07572396
Recruiting
Not Applicable

Clinical Effectiveness of a Motivational Interviewing-Based Conversational Mobile Application for High-Risk Drinkers

Alcohol DrinkingHigh-Risk Drinking Patterns
Yonsei University220 enrolled1 locationNCT07238998
Recruiting
Phase 2

A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.

High-Risk Localized Prostate Cancer
Bayer250 enrolled23 locationsNCT07450599
Recruiting
Not Applicable

Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention

ECMOHigh-risk PCI
Beijing Anzhen Hospital176 enrolled1 locationNCT06274411
Recruiting

Assessing Intellectual and Motor Outcomes in High-risk Infants

Motor impairmentCerebral PalsyCerebral Palsy (CP)+7 more
University College Cork600 enrolled4 locationsNCT06857539
Recruiting
Phase 2

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

High-risk R/R LBCL
Zhejiang Cancer Hospital20 enrolled1 locationNCT07538635
Recruiting
Not Applicable

Phase III Adaptive Adaptive Stereostactic Body Radiotherapy (SBRT) With Dose Escalation for High-Risk Prostate Cancer

High-risk Prostate Cancer
Center Eugene Marquis390 enrolled1 locationNCT07189598
Recruiting
Not Applicable

ELEVATE High-Risk PCI Pivotal Study

High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Magenta Medical Ltd.290 enrolled29 locationsNCT07001332
Recruiting

Serial PSMA PET for Therapy Monitoring in Clinically Significant Prostate Cancer

Treatment ResponseHigh-risk Prostate CancerPSMA PET+1 more
Xijing Hospital110 enrolled9 locationsNCT07553780
Recruiting
Phase 2

Phase II Study of RP2 as Immunoprevention in High-Risk Oral Precancerous Disease

High-Risk Oral Precancerous Disease
Glenn J. Hanna25 enrolled2 locationsNCT06623110
Recruiting
Phase 1Phase 2

Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT

LeukemiaInborn Errors of MetabolismHLH+11 more
Children's Hospital of Philadelphia100 enrolled1 locationNCT06839456
Recruiting
Phase 2

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Urothelial CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)+8 more
Michael A. O'Donnell174 enrolled1 locationNCT07322263
Recruiting
Phase 4

Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia

Perioperative Respiratory Adverse EventsHigh-RiskRespiratory Hypersensitivity+2 more
Sun Yat-sen University204 enrolled2 locationsNCT06624696